BioNTech SE is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. It develops pharmaceutical candidates based on messenger ribonucleic acid (mRNA) for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein repla… WebOct 21, 2024 · The Pfizer-BioNTech COVID-19 vaccine, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of Emergency Use Authorizations or equivalents in the …
BioNTech Puts Up $200M to Partner With OncoC4 in Cancer …
WebJun 23, 2024 · BioNTech's malaria vaccine candidates, which are based on its mRNA platform, are expected to enter human trials in 2024, according to a company press release. Vaccine inequities. WebJul 21, 2024 · Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the signing of a letter of intent with The Biovac Institute (Pty) Ltd, known as “Biovac,” a Cape Town-based, South African biopharmaceutical company, to manufacture the Pfizer-BioNTech COVID-19 Vaccine for distribution within the African Union. This … philip schmagold
EU Finalizes Agreement for Extra 300M Pfizer COVID-19 Vaccines
Web1 day ago · Biontech : Annual Financial Statements 2024 (German Version only) 02:55p: Biontech : Annual financial statements of BioNTech SE as of 31.12.2024 (German Version onl.. 04/12: Ipsen est bien placé pour réaliser de nouvelles acquisitions - DG: 04/11: Les valeurs pharmaceutiques et technologiques mènent les actions européennes à la hauss.. … WebSep 24, 2024 · BioNTech SE: ClinicalTrials.gov Identifier: NCT04101357 Other Study ID Numbers: BNT411-01 2024-003593-17 ( EudraCT Number ) First Posted: September 24, 2024 Key Record Dates: Last Update Posted: March 15, 2024 Last Verified: March 2024 Individual Participant Data (IPD) Sharing Statement: ... WebApr 11, 2024 · MAINZ, Germany, April 11, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) presented data from its ongoing first-in-human Phase 1/2 trial evaluating the ... truth about sandra bullock